Last reviewed · How we verify
Andion (ANISINDIONE)
Andion works by inhibiting Vitamin K-dependent gamma-carboxylase, an enzyme necessary for blood clotting.
Andion (ANISINDIONE) is a small molecule drug developed by SCHERING that targets Vitamin K-dependent gamma-carboxylase. It is an anisindione class medication, approved by the FDA in 1957 for certain indications. As an off-patent medication, there are no active Orange Book patents, and it is not currently manufactured by any generic manufacturers. Andion is used to treat certain conditions, but its exact indications and commercial status require further research. Key safety considerations are not well-documented due to the lack of available information.
At a glance
| Generic name | ANISINDIONE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | anisindione |
| Target | Vitamin K-dependent gamma-carboxylase, Arachidonate 5-lipoxygenase |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1957 |
Mechanism of action
Think of Vitamin K-dependent gamma-carboxylase like a key that helps blood clotting proteins work properly. Andion blocks this key, preventing blood clots from forming. This can be helpful in certain medical conditions, but it also means that people taking Andion may be at risk of bleeding more easily.
Approved indications
Common side effects
Drug interactions
- Vitamin E
- acetylsalicylic acid
- bismuth subsalicylate
- carbamazepine
- cholestyramine
- choline salicylate
- cimetidine
- clofibrate
- danazol
- diclofenac
- diflunisal
- disulfiram
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |